Author/Authors :
Barati, Mohammad Department of Immunology - Pasteur Institute of Iran, Tehran , Mohebali, Mehdi Department of Medical Parasitology and Mycology - School of Public Health - Tehran University of Medical Sciences, Tehran , Khamesipour, Ali Center for Research and Training in Skin Diseases and Leprosy - Tehran University of Medical Sciences, Tehran , Bahrami, Fariborz Department of Immunology - Pasteur Institute of Iran, Tehran , Darabi, Haiedeh Department of Immunology - Pasteur Institute of Iran, Tehran , Khaze, Vahid Department of Immunology - Pasteur Institute of Iran, Tehran , Riazi-Rad, Farhad Department of Immunology - Pasteur Institute of Iran, Tehran , Habibi, Gholamreza Razi Vaccine & Serum Research Institute, Karaj , Ajdary, Soheila Department of Immunology - Pasteur Institute of Iran, Tehran , Alimohammadian, Mohammad Hossein Department of Immunology - Pasteur Institute of Iran, Tehran
Abstract :
Background: We aimed to investigate the potential effects of BCG and imiquimod on improvement
of current experimental L. major vaccine against dogs in an endemic area of Zoonotic
visceral leishmaniasis (ZVL) in Iran.
Methods: During 2012 till 2014, seven mixed-breed shepherd dogs with no anti-Leishmania
antibodies and no response to Leishmanin reagent were immunized with 2 doses of alumprecipitated
autoclaved L. major (Alum-AML) while BCG and imiquimod (for skin pretreatment)
were used as adjuvants. The productions of a few characteristic cytokines of Thelper
immune responses and the development of delayed-type hypersensitivity (DTH) of the
immunized animals were then evaluated, up to 300 days. Blood samples were collected at 0,
30, 80 and 300 d post-vaccination and the concentrations of IFN-γ, IL10, IL-12 and TGF-β
cytokines secreted from PBMCs at these time-points were quantified by ELISA. DTH was
evaluated by Leishmanin skin test (LST).
Results: Although a similar LST conversion was observed at all time-points, the cytokine
measurement results indicated significantly higher levels of IFN-γ at day 80 and elevated levels
of IL-10 at days 80 and 300, post-vaccination. Moreover, a significantly higher IFN-γ/IL-10
ratio was observed at day 30 post-vaccination compared to the other time-points.
Conclusion: Although a Th1-like response could be observed at day 30 post-vaccination, the
development of cytokine profiles was inclined toward mixed Th1 and Th2 responses at days
80 and 300 post-vaccination. This situation may indicate the requirement of an additional
boosting by this Alum-AML formula, in order to induce long-lasting protection against ZVL.
Keywords :
Zoonotic visceral leishmaniasis (ZVL) , Alum-ALM vaccine , BCG and imiquimod adjuvant , Cytokines , Leishmanin skin test (LST)